An assessment of physician knowledge and understanding of the risks of vandetanib (Caprelsa®) within the European Union

First published 08/07/2013

Last updated 01/04/2024

EU PAS number:

EUPAS4242

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

Final Caprelsa prescriber survey protocol (2) (2)

English (313.16 KB - PDF)View document

Study results

Study results

Vandetanib Physican Survey Study Report - 22JUN2018

English (469.24 KB - PDF)View document

Study report

Other information

ENCePP Seal

ENCePP Seal documents